Last updated: September 14, 2026
MYLOTARG, or gemtuzumab ozogamicin, is a CD33-directed antibody-drug conjugate marketed by Pfizer for acute myeloid leukemia (AML). Its commercial history is defined by an initial withdrawal, a narrower reapproval in 2017, limited patient volume, hospital-based administration, and competition from intensive chemotherapy, targeted agents, venetoclax combinations, and other AML regimens.
Pfizer does not report MYLOTARG as a separately disclosed revenue line in its public financial statements. The product therefore appears to be a strategically maintained specialty oncology asset rather than a material contributor to Pfizer’s consolidated revenue.
What is MYLOTARG and how does it work?
MYLOTARG combines a recombinant anti-CD33 monoclonal antibody with the cytotoxic agent calicheamicin. CD33 is expressed on most AML blasts and on some normal myeloid cells. After binding to CD33, the conjugate is internalized and releases calicheamicin, which induces DNA damage.
| Attribute |
MYLOTARG |
| Active ingredient |
Gemtuzumab ozogamicin |
| Drug class |
Antibody-drug conjugate |
| Target |
CD33 |
| Disease |
CD33-positive AML |
| Sponsor |
Pfizer |
| Original U.S. approval |
May 2000 |
| U.S. withdrawal |
October 2010 |
| U.S. reapproval |
September 2017 |
| FDA application |
BLA 761060 |
| Administration |
Intravenous infusion |
| Primary commercial setting |
Hospital and specialist oncology care |
The product is used in newly diagnosed CD33-positive AML and in relapsed or refractory CD33-positive AML. The 2017 approval relied on a fractionated dosing regimen and a more defined patient population than the original approval.[1]
When did MYLOTARG lose and regain FDA approval?
MYLOTARG’s regulatory history has directly affected its market value.
Regulatory timeline
| Date |
Event |
Commercial effect |
| May 2000 |
FDA grants accelerated approval for relapsed CD33-positive AML |
Establishes first-mover position in AML antibody-drug conjugates |
| 2001-2010 |
Confirmatory studies produce safety and efficacy concerns |
Limits adoption and increases regulatory risk |
| October 2010 |
Pfizer withdraws MYLOTARG from the U.S. market |
U.S. revenue ends |
| June 2017 |
FDA advisory committee supports reapproval under revised use |
Reopens U.S. commercial opportunity |
| September 1, 2017 |
FDA approves MYLOTARG for selected adult and pediatric AML indications |
Restores U.S. sales |
| 2024 |
Seven-year orphan-drug exclusivity period from the 2017 approval expires |
Removes orphan exclusivity as a principal regulatory barrier |
The original withdrawal followed the SWOG S0106 trial, which did not demonstrate the expected benefit and showed higher early mortality in the MYLOTARG-containing arm. The FDA later approved a lower, fractionated regimen supported by clinical data showing improved benefit-risk performance.[1,2]
What is the current FDA status of MYLOTARG?
MYLOTARG remains an FDA-approved biologic for CD33-positive AML under BLA 761060. Its approved use covers adults with newly diagnosed disease, adults with relapsed or refractory disease, and pediatric patients at least two years old in specified settings.[3]
The product carries clinically important warnings, including:
- Hepatotoxicity and veno-occlusive disease
- Infusion-related reactions
- Hemorrhage
- Prolonged cytopenias
- Tumor lysis syndrome
- Embryo-fetal toxicity
The veno-occlusive disease risk is particularly relevant in patients proceeding to hematopoietic stem-cell transplantation. This risk can affect treatment sequencing, transplant planning, monitoring intensity, and institutional adoption.[3]
What is the exclusivity timeline for MYLOTARG?
MYLOTARG’s key U.S. regulatory exclusivity period began with the 2017 reapproval, not with the original 2000 approval.
Exclusivity profile
| Exclusivity type |
Relevant date or status |
| Original accelerated approval |
2000 |
| U.S. market withdrawal |
2010 |
| Reapproval |
September 1, 2017 |
| Orphan-drug exclusivity |
Generally seven years from the 2017 approval, expiring in 2024 |
| Biologic reference-product exclusivity |
The statutory 12-year period for the 2017 BLA would extend into 2029, subject to applicable regulatory interpretation |
| Pediatric exclusivity |
No separate six-month extension should be assumed without confirmation of an FDA-issued pediatric exclusivity period |
| Patent exclusivity |
Requires claim-by-claim review of active U.S. patents and terminal disclaimers |
The orphan exclusivity attached to the reapproved indications likely expired in 2024. It prohibited FDA approval of the same drug for the same disease or condition during the exclusivity period, subject to statutory exceptions.
Because MYLOTARG is a biologic approved under the Public Health Service Act, future competition would normally proceed through the 351(k) biosimilar pathway rather than through an abbreviated new drug application and conventional Paragraph IV certification.
What patents protect MYLOTARG?
MYLOTARG’s protection is likely divided among several patent categories:
- The anti-CD33 antibody or antibody sequence.
- The antibody-calicheamicin conjugate.
- Linker and conjugation chemistry.
- Manufacturing and purification methods.
- AML treatment methods and dosing regimens.
- Pharmaceutical compositions and infusion formulations.
The commercial importance of those categories is different. Composition-of-matter claims generally provide the strongest exclusionary position. Formulation and process claims may remain enforceable but often create narrower barriers. Method-of-use claims can be valuable when they cover fractionated dosing, patient selection, or combination treatment, but their enforcement depends on prescribing and labeling evidence.
No conventional Orange Book-based Paragraph IV analysis should be applied to MYLOTARG. FDA’s Orange Book primarily covers approved small-molecule drug products. Biologic reference products are tracked through the Purple Book and related FDA biologics records. A biosimilar applicant would rely on the 351(k) framework and would address patent information through the biologics patent-exchange process rather than an ANDA certification.
A definitive freedom-to-operate assessment would require current USPTO records, FDA Purple Book information, patent-family analysis, maintenance-fee status, terminal disclaimers, and any litigation or settlement records. Public Pfizer financial disclosures do not identify a standalone MYLOTARG patent estate or a product-specific litigation reserve.
Are there MYLOTARG Paragraph IV challenges or biosimilar competitors?
There is no conventional MYLOTARG Paragraph IV pathway because the product is a biologic rather than a small-molecule drug listed for ANDA substitution.
No widely commercialized U.S. biosimilar competitor to MYLOTARG has been established in the public market through the available product disclosures. The principal competitive risk is therefore not immediate pharmacy substitution. It is the potential development of a follow-on gemtuzumab ozogamicin product under the 351(k) pathway.
A follow-on product would face several practical barriers:
- Demonstrating analytical similarity for a complex antibody-drug conjugate
- Characterizing linker-payload distribution
- Matching antibody binding and internalization properties
- Addressing manufacturing comparability
- Generating sufficient pharmacology and immunogenicity data
- Navigating biologics patent litigation and the patent dance
- Establishing hospital and academic-center adoption
The complexity of an antibody-drug conjugate makes biosimilar development more demanding than development of a conventional monoclonal antibody.
How strong is the MYLOTARG patent estate?
MYLOTARG’s practical patent strength is moderate rather than clearly dominant.
The product has several structural advantages: an established biologic license, a recognized CD33 mechanism, clinical data, and a complex manufacturing process. Those factors can delay or increase the cost of follow-on development even if broad composition claims have expired.
Its weaknesses are equally important. The product was first approved in 2000, which places its earliest technology in an old patent cohort. The most valuable foundational claims may have expired or may be approaching the end of their enforceable terms. The 2017 reapproval did not restart the patent term for the underlying molecule. Later patents directed to dosing, formulation, or manufacturing may provide narrower protection than a surviving composition-of-matter patent.
The commercial barrier is therefore likely to depend more on development complexity, limited market size, and clinical positioning than on a single broad patent blocking all competition.
What is the market size and competitive position of MYLOTARG?
MYLOTARG operates in a specialized AML segment. AML is a serious but relatively small hematologic malignancy population compared with breast, lung, or prostate cancer. Only a subset of AML patients is CD33-positive, clinically appropriate for gemtuzumab, and treated in a setting where the product’s risks and logistics are acceptable.
Main competitive therapies
| Therapy |
Competitive relationship |
| Conventional cytarabine plus anthracycline induction |
Core comparator in fit newly diagnosed AML |
| Vyxeos, or CPX-351 |
Competes in therapy-related AML and AML with myelodysplasia-related changes |
| Venetoclax plus azacitidine or decitabine |
Major competitor in older or unfit patients |
| Midostaurin |
Competes in FLT3-mutated AML |
| Gilteritinib |
Competes in relapsed or refractory FLT3-mutated AML |
| Ivosidenib and enasidenib |
Compete in selected IDH-mutated AML |
| Oral azacitidine |
Competes in maintenance and post-remission settings |
| Stem-cell transplantation |
Affects sequencing and eligibility for MYLOTARG |
MYLOTARG’s strongest commercial position is in CD33-positive patients receiving intensive therapy where the treating team accepts the risk of hepatotoxicity and veno-occlusive disease. Its position is weaker in older or medically frail patients, where venetoclax-based regimens have become central to treatment.
How has the financial trajectory of MYLOTARG changed?
MYLOTARG had three distinct financial phases.
1. Initial launch and rapid risk accumulation
The 2000 launch created a specialty oncology franchise opportunity. Adoption was constrained by toxicity, uncertain confirmatory evidence, and the difficulty of identifying patients who would gain sufficient benefit.
2. Withdrawal and revenue interruption
The 2010 withdrawal removed U.S. sales and impaired the product’s commercial reputation. Pfizer continued to have international and investigational exposure, but the U.S. market was no longer available.
3. Reentry as a narrower specialty product
The 2017 reapproval restored a U.S. revenue stream but did not return the product to broad AML use. The revised indication, fractionated dosing, monitoring requirements, and competition from targeted combinations limited its addressable market.
Pfizer does not separately report MYLOTARG net product revenue in its annual reports. It is generally grouped within broader oncology or established-product categories. As a result, investors cannot derive a reliable product-level revenue trend from Pfizer’s consolidated disclosures alone.[4]
Financial implications
| Factor |
Effect on MYLOTARG |
| Small CD33-positive patient subset |
Limits volume |
| Inpatient administration |
Increases treatment complexity |
| Specialty oncology pricing |
Supports revenue per treated patient |
| Dosing and monitoring |
Raises hospital resource requirements |
| Veno-occlusive disease risk |
Can reduce physician adoption |
| Combination and sequencing competition |
Compresses eligible use |
| No separately reported revenue |
Limits external financial visibility |
| No established biosimilar |
Preserves current commercial position |
MYLOTARG is unlikely to be a material Pfizer earnings driver. Its value is more consistent with a niche oncology asset that generates targeted revenue, supports a broader hematology portfolio, and retains strategic value in clinical protocols.
What generic launch scenarios exist for MYLOTARG?
A conventional generic launch is not the relevant scenario. The likely competition paths are:
Biosimilar or follow-on biologic entry
A sponsor could develop a 351(k) biosimilar or a related biologic product. Entry would depend on analytical comparability, manufacturing economics, patent resolution, and market access.
Label-limited competition
A follow-on product might initially seek a narrower indication or avoid certain protected dosing claims. This could produce partial rather than full substitution.
Physician-led switching
Because MYLOTARG is administered intravenously in hospitals, automatic substitution may be less significant than in retail pharmacy markets. Formulary decisions, institutional protocols, and physician familiarity would likely determine uptake.
Clinical displacement
The greatest near-term threat is continued displacement by venetoclax-based regimens, FLT3 and IDH inhibitors, CPX-351, and evolving AML combinations. These therapies can reduce MYLOTARG use without directly competing through patent litigation.
What licensing deals and litigation affect MYLOTARG?
Pfizer owns and commercializes MYLOTARG in the United States. Public financial reporting does not identify a major current MYLOTARG licensing transaction, royalty burden, or product-specific settlement that materially changes the commercial outlook.
The original product was developed before Pfizer’s acquisition of Wyeth in 2009. The withdrawal and subsequent reapproval occurred within Pfizer’s portfolio-management and regulatory framework. No major active U.S. litigation involving a MYLOTARG biosimilar challenger is broadly disclosed in Pfizer’s recent public reporting.
The absence of disclosed litigation does not establish that no patent disputes exist. It indicates that no publicly reported dispute has become a material financial event for Pfizer.
What geographic markets support MYLOTARG?
MYLOTARG has regulatory and commercial relevance outside the United States, but market access varies by jurisdiction. Pricing, reimbursement, treatment guidelines, and national AML protocols determine use.
The United States remains important because of specialty oncology pricing and academic-center adoption. European and other markets may offer smaller revenue per patient and more restrictive health-technology assessment requirements. Geographic patent protection also depends on country-specific prosecution, maintenance, supplementary protection certificates, and national litigation.
Key Takeaways
- MYLOTARG is a niche CD33-targeted antibody-drug conjugate for selected AML patients.
- The product was approved in 2000, withdrawn in 2010, and reapproved in 2017 under a narrower treatment strategy.
- Its seven-year orphan exclusivity from the 2017 approval generally ended in 2024.
- MYLOTARG is a biologic, so conventional Paragraph IV generic challenges do not apply.
- No established U.S. biosimilar competitor is broadly commercialized.
- Patent strength likely depends on surviving antibody-drug conjugate, dosing, formulation, and manufacturing claims rather than the original approval date alone.
- Pfizer does not separately disclose MYLOTARG revenue, preventing a precise product-level financial trajectory.
- Commercial risk comes more from AML treatment displacement and limited patient volume than from immediate generic substitution.
- Veno-occlusive disease, infusion requirements, and hospital administration constrain adoption.
- The product remains commercially relevant as a specialized component of AML treatment, but it is unlikely to be a major Pfizer revenue driver.
FAQs about MYLOTARG market access and competition
Is MYLOTARG still available in the United States?
Yes. MYLOTARG remains FDA-approved and commercially available for specified CD33-positive AML indications under BLA 761060.
Does MYLOTARG have a generic equivalent?
No conventional generic equivalent is expected because MYLOTARG is a biologic. Any follow-on product would generally use the 351(k) biosimilar pathway.
Is MYLOTARG listed in the Orange Book?
MYLOTARG should not be analyzed through the standard Orange Book Paragraph IV framework used for small-molecule drugs. Biologic reference-product and patent information are handled through FDA biologics systems and the applicable biologics patent process.
What is the main clinical risk affecting MYLOTARG sales?
The principal product-specific risk is hepatotoxicity, including veno-occlusive disease. This risk is particularly important around hematopoietic stem-cell transplantation.
Which AML drugs most directly compete with MYLOTARG?
The closest competitive therapies include CPX-351, venetoclax combinations, conventional intensive induction, FLT3 inhibitors, IDH inhibitors, and post-remission or transplant-based strategies.
References
- U.S. Food and Drug Administration. (2017, September 1). FDA approves Mylotarg for treatment of acute myeloid leukemia. https://www.fda.gov
- U.S. Food and Drug Administration. (2010, October 25). FDA announces voluntary withdrawal of Mylotarg. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Mylotarg prescribing information. Pfizer Laboratories. https://labeling.pfizer.com
- Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. https://www.pfizer.com/investors/financial-information/annual-reports-proxies
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
